Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/fon-2016-0160 | DOI Listing |
Andes Pediatr
August 2024
Hemato-Oncología Infantil, Universidad Austral de Chile, Valdivia, Chile.
Unlabelled: L-asparaginase (L-asp) is an antineoplastic drug used in Leukemia and Lymphoma treatment protocols. Alterations in lipid metabolism have been reported in 10-50% of children treated with L-Asp.
Objective: To report an unusual complication of lipid metabolism associated with the use of L-Asp.
Br J Haematol
January 2025
Hematology Department, Versailles Hospital, Le Chesnay, France.
Hodgkin lymphoma (HL) is one of the most common cancers in adolescents and young adults (AYA). Paediatric and adult therapeutic strategies diverge while sharing the common objective: maintaining optimal efficacy with less long-term toxicity. However, few studies have compared the outcome of AYA treated according to one or the other approaches.
View Article and Find Full Text PDFIntroduction: Anal Lymphoma (AL) is a rare presentation of extranodal lymphomas, characterized by occurrence in the anal area and largely understudied due to its infrequency. This study aims to address gaps in knowledge about AL's demographic and clinical profiles, treatments, and survival outcomes, leveraging data from the SEER program.
Methods: We conducted a retrospective analysis of 79 AL cases identified in the SEER database from 2000 to 2022; 36 stage I AL were identified and defined as localized primary anal lymphoma (L-PAL).
Lancet Public Health
January 2025
Department of Oncology, University of Calgary, Calgary, AB, Canada; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada; Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Alberta Health Services, Arthur Child Comprehensive Cancer Centre, Calgary, AB, Canada. Electronic address:
Background: Adolescent and young adult (AYA) cancer survivors are at an increased risk of premature mortality due to their cancer and its treatment. Herein, we aimed to quantify the excess risks of mortality among AYA cancer survivors and identify target populations for intervention.
Methods: The Alberta AYA Cancer Survivor Study is a retrospective, population-based cohort of individuals diagnosed with a first primary neoplasm at age 15-39 years in Alberta, Canada, between 1983 and 2017.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!